Great day for the D3 study, today. The first 2 children have been screened for the study at the Prapokklao Hospital in Thailand.
Thanks to the MRC CTU and the PHPT team to coordinate this effort.
Through D3, we aim to assess whether the combination of DTG/3TC is just as effective as the standard of care in terms of virological suppression in children and adolescents. The trial will also compare the toxicity, adherence, tolerability, acceptability and quality of life in participants of this combination versus that of the standard of care.
To know more about the D3 study, visit the D3 webpage in this website.